Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review.
- Author:
Jae Ki CHOI
1
;
Sung Yeon CHO
;
Su Mi CHOI
;
Gyo Hui KIM
;
Sung Eun LEE
;
Seok LEE
;
Dong Wook KIM
;
Dong Gun LEE
Author Information
- Publication Type:Case Report
- Keywords: Cytomegalovirus; Colitis; Dasatinib
- MeSH: Colitis*; Cytomegalovirus*; Dasatinib*; Diarrhea; Ganciclovir; Gastrointestinal Hemorrhage; Hematologic Neoplasms*; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Treatment Outcome
- From:Infection and Chemotherapy 2018;50(2):153-159
- CountryRepublic of Korea
- Language:English
- Abstract: Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely. We describe five patients who developed cytomegalovirus (CMV) colitis during dasatinib treatment, in whom the colitis was initially confused with other causes. The patients, three with chronic myeloid leukemia, and two with acute lymphoblastic leukemia, were diagnosed with CMV colitis based on endoscopic and histologic findings. The patients who examined blood CMV polymerase chain reaction were all positive. The patients received antiviral therapy in the form of either ganciclovir or valganciclovir, and the overall treatment outcome was fair. These cases suggest that physicians should consider the possibility of CMV reactivation when treating diarrhea and/or hematochezia in patients on dasatinib.
